<DOC>
	<DOC>NCT00675493</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in Romania.</brief_summary>
	<brief_title>Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 and type 2 diabetics who are treated with human premix insulin (the selection of the subjects will be at the discretion of the individual physician). Subjects currently being treated with biphasic insulin aspart 30 Subjects who were previously enrolled in this study Subjects with a hypersensitivity to biphasic insulin aspart 30 or to any of the excipients Women who are pregnant or have the intention of becoming pregnant within next 6 months Children below 10 years of age</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>